ExpreS2ion Biotech Holding AB

ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.

The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.

The capable and flexible ExpreS2 platform is up for almost any protein expression challenge and constitutes the very core of the company.

The platform of choice from discovery to GMP production
Our patented ExpreS2 protein expression system is built for optimal discovery, preclinical development and GMP production of hard-to-express proteins used in vaccines and vaccine-like treatments.

The system is built upon non-viral fruit fly cells and has the ability to quickly establish stable polyclonal pools that provide high protein expression levels. Introduction of the protein to express in the system is conducted through the use of vector DNA containing a constitutive proprietary hybrid promoter. Proven by world-class research teams
ExpreS2 has been proven to handle some of the world’s most difficult protein challenges, including the expression of proteins for several high-profile malaria vaccines under development. In these projects we work together with development/consortium partners such as Jenner Institute at the University of Oxford and Walter and Eliza Hall Institute of Medical Research.